02.23.15
Partnering to produce slow-release omega-3 tablets from a variety of oils, including shrimp, krill, algal and fish oils, BlueOcean NutraSciences and CMAX Technologies have signed a joint venture agreement that combines BlueOcean's supply and marketing expertise with CMAX's proprietary formulation technology. These tablets target the rapidly growing omega-3 and astaxanthin dietary supplements markets.
Tablet formulation development work is underway with commercially ready slow-release tablet samples from omega-3 fish oils expected in March 2015 from CMAX's tableting facility in Toronto, Canada. The joint venture will also produce tablets from BlueOcean's supply of shrimp oil ingredients, as well as provide custom tablet formulations for customers using their preferred omega-3 fish, krill and algal oils.
Slow-release tableting of omega-3/astaxanthin oils is a new formulation for these essential dietary supplements which are currently available in standard gel caps. CMAX's tableting technology is currently being used in the pharmaceutical industry for the formulation of a number of BCS class 2 drugs currently awaiting FDA approval. These slow-release omega tablets will be much smaller and easier to swallow than standard omega-3 gel caps.
CMAX's patent-pending slow-release technology has been proven to result in dramatic bioavailability increases in pharmaceutical applications. The slow-release omega-3 tablets will also be formulated for maximum bioavailability versus standard omega-3 fish oil gel caps.
Tablet formulation development work is underway with commercially ready slow-release tablet samples from omega-3 fish oils expected in March 2015 from CMAX's tableting facility in Toronto, Canada. The joint venture will also produce tablets from BlueOcean's supply of shrimp oil ingredients, as well as provide custom tablet formulations for customers using their preferred omega-3 fish, krill and algal oils.
Slow-release tableting of omega-3/astaxanthin oils is a new formulation for these essential dietary supplements which are currently available in standard gel caps. CMAX's tableting technology is currently being used in the pharmaceutical industry for the formulation of a number of BCS class 2 drugs currently awaiting FDA approval. These slow-release omega tablets will be much smaller and easier to swallow than standard omega-3 gel caps.
CMAX's patent-pending slow-release technology has been proven to result in dramatic bioavailability increases in pharmaceutical applications. The slow-release omega-3 tablets will also be formulated for maximum bioavailability versus standard omega-3 fish oil gel caps.
